Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
2 Dividend Giants Every Passive Income Investors Should Own
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
Johnson & Johnson (JNJ) shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
J&J CFO Joseph Wok on Q2 results: 2025 is shaping up to be better than what we'd thought
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, raising FY guidance, drug pipeline outlook, and more.
Johnson & Johnson Tops Q2 Estimates, Lifts Outlook for Sales and Profit
Johnson & Johnson (JNJ) on Wednesday lifted its full-year projections and reported second quarter results that beat estimates.
Johnson & Johnson (NYSE: JNJ) Live Earnings Updates: Will The Dividend Champion Deliver?
Johnson & Johnson reports before the bell today. The stock is popular in part thanks to its 3.3% dividend yield.
Johnson & Johnson's stock rallies after earnings beat and outlook raised, amid strength in heart and cancer treatments
Shares of Johnson & Johnson JNJ-1.05% climbed 1.6% in premarket trading Wednesday, after the drugmaker beat second-quarter earnings expectations and raised its full-year outlook, amid strength in sales of cancer treatments and heart health monitoring products.
Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales
Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on Wednesday as strong demand for its cancer drug, Darzalex, and strength in its medical device business helped it beat Wall Street expectations.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?
Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an important strategy, possibly improving the odds in your favor.
